Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Radue, Ernst-Wilhelm; Stuart, William; Calabresi, Peter; Confavreux, Christian; Galetta, Steven; Rudick, Richard; Lublin, Fred; Weinstock-Guttman, Bianca; Wynn, Daniel; Fisher, Elizabeth; Papadopoulou, Athina; Lynn, Frances; Panzara, Michael; Sandrock, Alfred; Fazekas, F.; Enzinger, C.; Seifert, T.; Storch, M.; Strasser-Fuchs, S.; Berger, T.; Dilitz, E.; Egg, R.; Deisenhammer, F.; Decoo, D.; Lampaert, J.; Bartholome, E.; Bier, J.; Stenager, E.; Rasmussen, M.; Binzer, M.; Shorsh, K.; Christensen, M.; Ravnborg, M.; Sorensen, P.; Blinkenberg, M.; Petersen, B.; Hansen, H.; Bech, E.; Petersen, T.; Kirkegaard, M.; Eralinna, J.; Ruutiainen, J.; Soilu-Hanninen, M.; Sako, E.; Laaksonen, M.; Reunanen, M.; Remes, A.; Keskinarkaus, I.; Moreau, T.; Noblet, M.; Rouaud, O.; Couvreur, G.; Edan, G.; LePage, E.; Drapier, S.; De Burghgraeve, V.; Yaouanq, J.; Merienne, M.; Cahagne, V.; Gout, O.; Deschamps, R.; Le Canuet, P.; Moulignier, A.; Vermersch, P.; De Seze, J.; Stojkovic, T.; Griffie, G.; Engles, Engles; Ferriby, D.; Debouverie, M.; Pittion-Vouyouvitch, S.; Lacour, J.; Pelletier, J.; Feuillet, L.; Suchet, L.; Dalecky, A.; Tammam, D.; Lubetzki, C.; Youssov, K.; Mrejen, S.; Charles, P.; Yaici, S.; Clavelou, P.; Aufauvre, D.; Renouil-Guy, N.; Cesaro, P.; Degos, F.; Benisty, S.; Rumbach, L.; Decavel, P.; Confavreux, C.; Blanc, S.; Aubertin, P.; Riche, G.; Brochet, B.; Ouallet, J.; Anne, O.; Menck, S.; Grupe, Grupe; Guttman, Guttman; Lensch, E.; Fucik, E.; Heitmann, S.; Hartung, H.; Schroter, M.; Kurz, F.; Heidenreich, F.; Trebst, C.; Pul, R.; Hohlfeld, R.; Krumbholz, M.; Pellkofer, H.; Haas, J.; Segert, A.; Meyer, R.; Anagnostou, P.; Kabus, C.; Poehlau, D.; Schneider, K.; Hoffmann, V.; Zettl, U.; Steinhagen, V.; Adler, S.; Steinbrecher, A.; Rothenfusser-Korber, E.; Baum, K.; Gunther, A.; Blasing, H.; Stoll, G.; Gold, R.; Bayas, A.; Kleinschnitz, C.; Limmroth, V.; Katsarava, Z.; Kastrup, O.; Haller, P.; Stoeve, S.; Hobel, D.; Oschmann, P.; Voigt, K.; Burger, C.; Abramsky, O.; Karusiss, D.; Achiron, A.; Kishner, I.; Stern, Y.; Sarove-Pinhas, I.; Dolev, M.; Magalashvili, D.; Pozzili, C.; Lenzi, D.; Scontrini, A.; Millefiorini, E.; Buttinelli, C.; Gallo, P.; Ranzato, F.; Tiberio, M.; Perini, P.; Laroni, A.; Marrosu, M.; Cocco, E.; Marchi, P.; Spinicci, G.; Massole, S.; Mascia, M.; Floris, G.; Trojano, M.; Bellacosa, A.; Paolicelli, D.; Zimatore, G.; Simone, I.; Giorelli, M.; Di Monte, E.; Mancardi, G.; Pizzorno, M.; Murialdo, A.; Narciso, E.; Capello, A.; Comi, G.; Martinelli, V.; Rodegher, M.; Esposito, F.; Colombo, B.; Rossi, P.; Polman, C.; Jasperse, M.; Zwemmer, J.; Nielsen, J.; Kragt, J.; Jongen, P.; De Smet, E.; Tacken, H.; Frequin, S.; Siegers, H.; Mauser, H.; Fernandez-Fernandez, O.; Leon, A.; Romero, F.; Alonso, A.; Tamayo, J.; Nos, C.; Pelayo, R.; Tellez, N.; Rio, J.; Tintore, M.; Arbizu, T.; Romero, L.; Moral, E.; Martinez, S.; Kappos, L.; Achtnichts, L.; Wilmes, S.; Karabudak, R.; Kurne, A.; Erdem, S.; SİVA, AKSEL; Saip, S.; Altintas, A.; Atamer, A.; Eraksoy, M.; Bilgili, F.; Topcular, B.; Giovannoni, G.; Lim, E.; Lava, N.; Murnane, M.; Dentinger, M.; Zimmerman, E.; Reiss, M.; Gupta, V.; Scott, T.; Brillman, J.; Kunschner, L.; Wright, D.; Perel, A.; Babu, A.; Rivera, V.; Killian, J.; Hutton, G.; Lai, E.; Picone, M.; Cadivid, D.; Kamin, S.; Shanawani, M.; Gauthier, S.; Morgan, A.; Buckle, G.; Margolin, D.; Weinstock-Guttman, B.; Kwen, P.; Garg, N.; Munschauer, F.; Khatri, B.; Rassouli, M.; Saxena, V.; Ahmed, A.; Turner, A.; Fox, E.; Couch, C.; Tyler, R.; Horvit, A.; Fodor, P.; Humphries, S.; Wynn, D.; Nagar, C.; O'Brien, D.; Allen, N.; Turel, A.; Friedenberg, S.; Carlson, J.; Hosey, J.; Crayton, H.; Richert, J.; Tornatore, C.; Sirdofsky, M.; Greenstein, J.; Shpigel, Y.; Mandel, S.; Adbelhak, T.; Schmerler, M.; Zadikoff, C.; Rorick, M.; Reed, R.; Elias, S.; Feit, H.; Angus, E.; Sripathi, N.; Herbert, J.; Kiprovski, K.; Qu, X.; Del Bene, M.; Mattson, D.; Hingtgen, C.; Fleck, J.; Horak, H.; Javerbaum, J.; Elmore, R.; Garcia, E.; Tasch, E.; Gruener, G.; Celesia, G.; Chawla, J.; Miller, A.; Drexler, E.; Keilson, M.; Wolintz, R.; Drasby, E.; Muscat, P.; Belden, J.; Sullivan, R.; Cohen, J.; Stone, L.; Marrie, R.; Fox, R.; Hughes, B.; Babikian, P.; Jacoby, M.; Doro, J.; Puricelli, M.; Rossman, H.; Boudoris, W.; Belkin, M.; Pierce, R.; Zellner, Zellner; Montalban, X.; Eggenberger, E.; Birbeck, G.; Martin, J.; Kaufman, D.; Stuart, W.; English, J.; Stuart, D.; Gilbert, R.; Kaufman, M.; Putman, S.; Diedrich, A.; Follmer, R.; Pelletier, D.; Waubant, E.; Cree, B.; Genain, C.; Goodin, D.; Guarnaccia, J.; Patwa, H.; Rizo, M.; Kitaj, M.; Blevins, J.; Smith, T.; McGee, F.; Honeycutt, W.; Brown, M.; Isa, A.; Nieves-Quinones, D.; Krupp, L.; Smiroldo, J.; Zarif, M.; Perkins, C.; Sumner, A.; Fisher, A.; Gutierrez, Gutierrez; Jacoby, R.; Svoboda, S.; Dorn, D.; Groeschel, A.; Steingo, B.; Kishner, R.; Cohen, B.; Melen, O.; Simuni, T.; Zee, P.; Cohan, S.; Yerby, M.; Hendin, B.; Levine, T.; Tamm, H.; Travis, L.; Freedman, S.; Tim, R.; Ferrell, W.; Stefoski, D.; Stevens, S.; Katsamakis, G.; Topel, J.; Ko, M.; Gelber, D.; Fortin, C.; Green, B.; Logan, W.; Carpenter, D.; Temple, L.; Sadiq, S.; Sylvester, A.; Sim, G.; Mihai, C.; Vertino, M.; Jubelt, B.; Mejico, L.; Phillips, J.; Martin, A.; Heitzman, D.; Greenfield, C.; Riskind, P.; Cabo, A.; Paskavitz, J.; Moonis, M.; Bashir, K.; Brockington, J.; Nicholas, A.; Slaughter, R.; Archer, R.; Harik, S.; Haddad, N.; Pippenger, M.; Van den Noort, S.; Thai, G.; Olek, M.; Demetriou, M.; Shin, R.; Calabresi, P.; Rus, H.; Bever, C.; Johnson, K.; Sheremata, W.; Delgado, S.; Sherbert, R.; Herndon, R.; Uschmann, H.; Chandler, A.; Markowitz, C.; Jacobs, D.; Balcer, L.; Mitchell, G.; Chakravorty, S.; Heyman, R.; Stauber, Z.; Goodman, A.; Segal, B.; Schwid, S.; Samkoff, L.; Levin, M.; Jacewicz, M.; Menkes, D.; Pulsinelli, W.; Frohman, E.; Racke, M.; Hawker, K.; Ulrich, R.; Panitch, H.; Hamill, R.; Tandon, R.; Dulaney, E.; Simnad, V.; Miller, J.; Wooten, G.; Harrison, M.; Bowen, J.; Doherty, M.; Wundes, A.; Garden, G.; Distad, J.; Kachuck, N.; Berkovich, R.; Burnett, M.; Sahai, S.; Bandari, D.; Weiner, L.; Storey, J.; Beesley, B.; Hart, D.; Moses, H.; Sriram, S.; Fang, J.; O'Duffy, A.; Kita, M.; Taylor, L.; Elliott, M.; Roberts, J.; Jeffery, D.; Maxwell, S.; Lefkowitz, D.; Kumar, S.; Sinclair, M.

doi:10.1016/j.jns.2010.02.012

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Radue E., Stuart W. H., Calabresi P. A., Confavreux C., Galetta S. L., Rudick R. A., ...Daha Fazla

JOURNAL OF THE NEUROLOGICAL SCIENCES, cilt.292, ss.28-35, 2010 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 292
Basım Tarihi: 2010
Doi Numarası: 10.1016/j.jns.2010.02.012
Dergi Adı: JOURNAL OF THE NEUROLOGICAL SCIENCES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.28-35
Anahtar Kelimeler: Natalizumab, Interferon beta-1a, Multiple sclerosis, Integrin, Adhesion molecule inhibitor, Treatment, Magnetic resonance imaging, PLACEBO-CONTROLLED TRIAL, RESONANCE-IMAGING FINDINGS, T1 HYPOINTENSE LESIONS, SPIN-ECHO MRI, BRAIN ATROPHY, DOUBLE-BLIND, DISEASE PROGRESSION, GLATIRAMER ACETATE, OPEN-LABEL, SERIAL
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFN beta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n = 589) or placebo (n = 582) intravenously every 4 weeks plus IFN beta-1a 30 mu g intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFN beta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFN beta-1a alone. The mean change from baseline in 12 lesion volume over 2 years decreased in patients receiving natalizumab plus IFN beta-1a and increased in those receiving IFN beta-1a alone (-277.5 mm(3) versus 525.6 mm(3); p<0.001). Compared with IFN beta-1a alone, add-on natalizumab therapy resulted in a smaller increase in mean T1-hypointense lesion volume after 2 years (18213 mm(3) versus 2210.5 mm(3); p<0.001), a smaller mean number of new T1-hypointense lesions over 2 years (2.3 versus 4.1; p<0.001), and a slower rate of brain atrophy during the second year of therapy (-031% versus -0.40%; p = 0.020). Natalizumab add-on therapy reduced gadolinium-enhancing, T1-hypointense, and 12 MRI lesion activity and slowed brain atrophy progression in patients with relapsing MS who experienced disease activity despite treatment with IFN beta-1a alone. (C) 2010 Elsevier B.V. All rights reserved.